What does elutia (cormatrix) — financial royalty assets, net mean?

This is the carrying value of royalty assets for the Elutia and CorMatrix segments after deducting the allowance for credit losses. It represents the net economic value the company expects to recover from these specific royalty streams. This figure is critical for assessing the current fair value and liquidity potential of the company's intellectual property portfolio.

Ligand Pharmaceuticals (LGND) Elutia (CorMatrix) — Financial Royalty Assets, Net

Screener

Other product segments

Qarziba

$100.84M—

Similar metrics at other companies

RPRXCash collections from financial royalty assets

$814.85M+12.2%

RPRXCash collections from financial royalty assets

$814.85M+12.2%

RPRXCash collections from financial royalty assets

$814.85M+12.2%

KTBRoyalty — Net revenues

$14.43M+26.0%

SNRoyalty — Net Sales

$3.2M-16.3%

BCRXRoyalty Financing Liabilities

$426.79M-11.7%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	June 30, 2026 / Gross carrying value(1)	June 30, 2026 / Allowance	June 30, 2026 / Net carrying value (1)	December 31, 2025 / Gross carrying value(1)	December 31, 2025 / Allowance	December 31, 2025 / Net carrying value(1)
Agenus Bot/Bal	40,815	(408)	40,407	40,815	(408)	40,407
Tolerance Therapeutics (Tzield®)	25,470	(99)	25,371	25,257	(98)	25,159
Ohtuvayre inventors	19,957	(179)	19,778	16,921	(151)	16,770
Elutia (CorMatrix)	6,062	(837)	5,225	6,607	(1,107)	5,500
AT220	4,442	(109)	4,333	5,132	(132)	5,000
Primrose mRNA	3,281	(98)	3,183	3,281	(98)	3,183
Zerion	2,640	(79)	2,561	—	—	—
Others	5,729	(212)	5,517	5,769	(214)	5,555

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's elutia (cormatrix) — financial royalty assets, net?: Ligand Pharmaceuticals (LGND) reported elutia (cormatrix) — financial royalty assets, net of $5.23M in Q2 2026.
What does elutia (cormatrix) — financial royalty assets, net mean?: This is the carrying value of royalty assets for the Elutia and CorMatrix segments after deducting the allowance for credit losses. It represents the net economic value the company expects to recover from these specific royalty streams. This figure is critical for assessing the current fair value and liquidity potential of the company's intellectual property portfolio.